A Dedifferentiation Strategy to Enhance the Osteogenic Potential of Dental Derived Stem Cells by Paduano, Francesco et al.
                                                                    
University of Dundee
A Dedifferentiation Strategy to Enhance the Osteogenic Potential of Dental Derived
Stem Cells
Paduano, Francesco; Aiello, Elisabetta; Cooper, Paul R.; Marrelli, Benedetta; Makeeva, Irina
M.; Islam, Mohammad
Published in:






Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Paduano, F., Aiello, E., Cooper, P. R., Marrelli, B., Makeeva, I. M., Islam, M., Spagnuolo, G., Maged, D., De
Vito, D., & Tatullo, M. (2021). A Dedifferentiation Strategy to Enhance the Osteogenic Potential of Dental
Derived Stem Cells. Frontiers in Cell and Developmental Biology, 9, [668558].
https://doi.org/10.3389/fcell.2021.668558
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 29. May. 2021
fcell-09-668558 May 24, 2021 Time: 16:54 # 1
ORIGINAL RESEARCH




Marche Polytechnic University, Italy
Reviewed by:
Giacomina Brunetti,
University of Bari Aldo Moro, Italy
Waruna Lakmal Dissanayaka,









This article was submitted to
Stem Cell Research,
a section of the journal
Frontiers in Cell and Developmental
Biology
Received: 16 February 2021
Accepted: 30 April 2021
Published: 28 May 2021
Citation:
Paduano F, Aiello E, Cooper PR,
Marrelli B, Makeeva I, Islam M,
Spagnuolo G, Maged D, De Vito D
and Tatullo M (2021) A
Dedifferentiation Strategy to Enhance
the Osteogenic Potential of Dental
Derived Stem Cells.
Front. Cell Dev. Biol. 9:668558.
doi: 10.3389/fcell.2021.668558
A Dedifferentiation Strategy to
Enhance the Osteogenic Potential of
Dental Derived Stem Cells
Francesco Paduano1* , Elisabetta Aiello1, Paul Roy Cooper2, Benedetta Marrelli1,
Irina Makeeva3, Mohammad Islam4, Gianrico Spagnuolo5, Davide Maged6,
Danila De Vito7 and Marco Tatullo7*
1 Stem Cells and Medical Genetics Units, Biomedical Section, Tecnologica Research Institute and Marrelli Health, Crotone,
Italy, 2 Faculty of Dentistry, Sir John Walsh Research Institute, University of Otago, Dunedin, New Zealand, 3 Department of
Therapeutic Dentistry, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 4 Department of Oral Surgery
and Medicine, The Dental School, University of Dundee, Dundee, United Kingdom, 5 Department of Neurosciences,
Reproductive and Odontostomatological Sciences, University of Naples “Federico II,” Naples, Italy, 6 EMS—Elite Medical
Services Ltd., Cairo, Egypt, 7 Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari
“Aldo Moro,” Bari, Italy
Dental stem cells (DSCs) holds the ability to differentiate into numerous cell types. This
property makes these cells particularly appropriate for therapeutic use in regenerative
medicine. We report evidence that when DSCs undergo osteogenic differentiation,
the osteoblast-like cells can be reverted back to a stem-like state and then further
differentiated toward the osteogenic phenotype again, without gene manipulation. We
have investigated two different MSCs types, both from dental tissues: dental follicle
progenitor stem cells (DFPCs) and dental pulp stem cells (DPSCs). After osteogenic
differentiation, both DFPCs and DPSCs can be reverted to a naïve stem cell-like status;
importantly, dedifferentiated DSCs showed a greater potential to further differentiate
toward the osteogenic phenotype. Our report aims to demonstrate for the first time that
it is possible, under physiological conditions, to control the dedifferentiation of DSCs
and that the rerouting of cell fate could potentially be used to enhance their osteogenic
therapeutic potential. Significantly, this study first validates the use of dedifferentiated
DSCs as an alternative source for bone tissue engineering.
Keywords: dental stem cells (DSCs), dental follicle progenitor stem cells (DFPCs), dental pulp stem cells (DPSCs),
stem cell fate, dedifferentiation
INTRODUCTION
Bone loss occurring after trauma or diseases is one of the main issues affecting the quality of life
of many people worldwide (Paduano et al., 2017). Up to now, autologous bone transplantation
has been considered the gold standard for the treatment for bone defects; however, it has
several limitations, such as morbidity at the donor site and the limited availability of grafting
material (Paduano et al., 2017). Therefore, new strategies are needed for the treatment and repair
of bone defects.
Mesenchymal stem cells (MSCs) of dental origin, due to their multilineage differentiation
ability, are considered a suitable cell source for clinical applications (Chatzivasileiou et al., 2013;
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Paduano et al., 2016; Ballini et al., 2017, 2018). However,
there are several issues still to overcome before DSCs can
be used in bone cell therapy. Dental stem cells (DSCs), like
other MSC types, can exhibit a relatively low cell survival rate
and differentiation potential in vivo, and this can significantly
reduce their effectiveness in stem cell therapy, and thus
their clinical usage (Liu et al., 2011; Rui et al., 2015).
Consequently, it is of considerable interest to explore novel
strategies to improve the regenerative commitment of DSCs.
In this context, several researchers have demonstrated that the
dedifferentiation process provides an interesting strategy for
improving the ultimate differentiation potential of MSCs in vivo
(Liu et al., 2011).
It has been hypothesised that fully differentiated mammalian
cells are unable to undertake reverse cell differentiation, a
process known as “dedifferentiation” (Zhang et al., 2010).
However, recent evidence has shown that specific cells, such
as epidermal cells, could be stimulated to dedifferentiate when
exposed to specific stimuli, resulting in the reversion of cells to
a less differentiated and more pluripotent state (Zhang et al.,
2010). Indeed, it is also well known that somatic cells of
human origin can be induced to dedifferentiate into induced
pluripotent stem cells (iPSCs) by introducing the Yamanaka
transcription factors Klf4, c-Myc, Sox-2, and Oct4 (Pennock et al.,
2015). However, until now, dedifferentiation of cells has been
mainly obtained by nuclear reprogramming, which is a non-
physiological process.
Recently, dedifferentiation has been considered for
therapeutic application to enable the rerouting of cell fate
by inducing the reversion of differentiated cells to a less
differentiated state. This is subsequently characterised by an
increased differentiation potential (Odelberg et al., 2000).
In 2005, a study demonstrated that MSCs isolated from
rat bone marrow, without gene manipulation, could be
reprogrammed in vitro through osteogenic differentiation
and dedifferentiation, resulting in cells having an increased
capacity to form ectopic bone in nude mice (Rui et al., 2015).
Following this dedifferentiation process, MSCs can be reverted
to more primitive stem cells with improved osteogenic potential,
cell survival, migratory capacity, colony-forming ability and
increased expression of Oct4, Sox2, and Nanog (Rui et al.,
2015). Furthermore, a more recent study has provided evidence
that MSCs reprogrammed through neuronal differentiation
and dedifferentiation are more therapeutically efficacious (Liu
et al., 2011). These findings are clearly of significant interest as
they potentially provide a physiological approach to overcome
the limitations of iPSC, such as their genomic instability,
tumorigenicity and immunogenicity (Lu and Zhao, 2013).
While some evidence shows that differentiated MSCs possess
the ability to dedifferentiate into immature progenitors without
genetic manipulation (Zhang et al., 2010; Sawa et al., 2019),
no studies have shown whether DSCs have the ability to
dedifferentiation into a stem cell-like state. Thus, this study
investigated if DSCs can be dedifferentiated into a stem cell-
like state without gene manipulation and if the dedifferentiation
process can efficiently enhance the osteogenic capacity of DSCs
in vitro.
This study aimed at evaluating the dedifferentiation strategy
and its potential for enhancing the therapeutic efficacy of DSCs
for bone-regenerative medicine applications.
RESULTS
Osteogenic Dedifferentiated DFPCs
DFPCs used in this study express the typical MSC surface
markers and possess the ability to form colony-forming
units (CFU-F) and the multilineage differentiation potential
(Supplementary Figures 1–3).
The methods used to drive the osteogenic differentiation,
dedifferentiation and redifferentiation of DFPCs are
schematically illustrated in Figure 1A. Briefly, undifferentiated
DFPCs were induced in osteogenic medium for 10 days (Osteo-
DFPCs), washed in PBS, and then re-incubated with the basal
medium for a further 10 days (Dediff-DFPCs); redifferentiation
was subsequently achieved using the osteogenic medium for
another 10 days (Rediff-DFPCs, Figure 1A). To characterise
the osteogenic commitment of DFPCs in each differentiation
state, calcium deposits were assayed by Alizarin Red staining
(Figure 1B). Withdrawal of osteogenic medium for 10 days
reverted DFPC-derived osteogenic-like cells (Osteo-DFPCs) to
cells with characteristic mesenchymal morphology and with
reduced formation of mineralised nodules (Dediff-DFPCs).
Intriguingly, these Dediff-DFPCs derived from differentiated
osteogenic cultures (Osteo-DFPCs) could be re-induced into an
osteogenic phenotype on re-exposure to osteogenic medium for
10 days (Rediff-DFPCs).
Importantly, results revealed that after 10 days of osteogenic
induction medium, the presence of mineralisation was observed
in both Rediff-DFPCs and Osteo-DFPCs. However, we detected
a significantly higher Alizarin Red staining in Rediff-DFPCs
than Osteo-DFPCs (Figure 1B). Also, spectrophotometric
quantification of alizarin red staining indicated a higher
mineralisation and calcium uptake in the Rediff-DFPCs
than for the Osteo-DFPCs (Figure 1C). Importantly, Dediff-
DFPCs retained their immunophenotype similar to that of
undifferentiated DFPCs (Figure 1D).
Considering these interesting results, we subsequently
compared osteogenic differentiation between Rediff-DFPCs
and DFPCs cultured for 30 days in osteogenic medium (Osteo
30 days-DFPCs), the method widely used to differentiate
MSCs toward an osteogenic lineage. Transcript levels of
osteogenic-related genes were also assessed by qRT-PCR.
As shown in Figure 1E, results demonstrated that the early
inducer of osteogenic commitment runt-related transcription
factor 2 (Runx-2), as well as the mature osteoblast marker
osteocalcin (OSC) and bone-related protein osteonectin
(ON), were significantly increased in Rediff-DFPCs compared
with DFPCs cultured for 30 days in osteogenic medium
(Osteo-30 days-DFPCs).
Taken together, these data demonstrated the enhanced
expression of osteogenic-related transcripts in the Rediff-DFPCs
derived from Dediff-DFPCs compared with Osteo 30 days-
DFPCs. These data indicated that Dediff-DFPCs maintained
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FIGURE 1 | Osteogenic differentiation (Osteo-DFPCs), dedifferentiation (Dediff-DFPCs), and redifferentiation (Rediff-DFSCs) of DFPCs. (A) Schematic representation
showing the technique for deriving Osteo-DFPCs, Dediff-DFPCs, and Rediff-DFPCs as described in the Materials and Methods. Briefly, undifferentiated DFPCs were
stimulated for 10 days in osteogenic medium, rinsed in PBS, and then re-incubated for another 10 days with basal medium; redifferentiation was subsequently
achieved using the osteogenic medium for another 10 days. (B) Alizarin Red stained images showing the presence of calcium deposition produced by DFPCs. The
untreated DFPCs, Osteo-DFPCs, Dediff-DFPCs, and Rediff-DFPCs were incubated with (-MEM or osteogenic induced medium following the schematic provided in
(A), then DSCs were fixed and subjected to Alizarin Red staining. (C) Alizarin red quantification showing calcium deposition in Osteo-DFPCs, Dediff-DFPCs, and
Rediff-DFPCs compared to DFPCs control. *P < 0.05 and **P < 0.01. DFPCs cultured in osteogenic medium for 30 days were used as a positive control for
osteogenic differentiation (Osteo 30 days-DFPCs). (D) Cell surface markers of DFPCs and Dediff-DFPCs. (E) Relative mRNA expression levels of Runx2, OSC, and
ON assayed by qRT-PCR in Osteo-DFPCs, Dediff-DFPCs, and Rediff-DFPCs compared to DFPCs control. HPRT mRNA levels were used for normalisation. The data
are shown as mean ± SD (n = 3), *P < 0.05, compared to Osteo 30 days-DFPCs. (F) Relative ALP activity in Osteo-DFPCs, Dediff-DFPCs and Rediff-DFPCs
compared to DFPCs control. (G) mRNA expression of the stemness-associated genes Sox2, Klf4, and Nanog in Dediff-DFPCs and Osteo-DFPCs compared with
DFPCs. Data are shown as fold increase with respect to mRNA level expressed in undifferentiated DFPCs. *P < 0.05.
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osteogenic commitment, and therefore, a higher capacity to
redifferentiate toward the osteogenic phenotype. In addition, as
displayed in Figure 1F, Rediff-DFPCs also showed an increase of
ALP activity compared with Osteo 30 days-DFPCs.
As Sox2, KLf4, and Nanog are key pluripotent genes necessary
for reprogramming iPSCs and embryonic stem cell (ESC)
pluripotency, we investigated their expression using qRT-PCR.
Interestingly, results showed a significantly higher expression of
Sox2, KLf4, and Nanog in Dediff-DFPCs than untreated DFPCs,
suggesting a more primitive phenotype of dedifferentiated DFPCs
(Dediff-DFPCs, Figure 1G). These results indicated that the
stemness genes Sox2, Klf4, and Nanog play a crucial role in
maintaining the self-renewal state in Dediff-DFPCs.
Interestingly, Dediff-DFPCs exhibited advantages in





As DPSCs are the most widely studied and well-characterised
DSC type [3,4], we investigated the osteogenic differentiation
capacity of dedifferentiated DPSCs (Dediff-DPSCs). As observed
previously for DFPCs, DPSCs used in this study also express
the typical MSC surface markers and possess the ability
to form colony-forming units (CFU-F) and the multilineage
differentiation potential (Supplementary Figures 2–4).
Importantly, we compared the osteogenic potential of Rediff-
DPSCs not only with that of undifferentiated DPSCs but also with
that of DPSCs grown in osteogenic medium for 30 days (Osteo
30 days-DPSCs), the standard method used to differentiate
DPSCs into osteogenic-like cells in vitro (Marrelli et al., 2013;
Barry et al., 2016).
The approach used to stimulate osteogenic differentiation,
dedifferentiation, redifferentiation and osteogenic differentiation
for 30 days of DPSCs (Osteo 30 days-DPSCs) is schematically
identical to Figure 1A. As observed previously for DFPCs, the
Dediff-DPSCs derived from differentiated osteogenic cultures
(Osteo-DPSCs) could also be re-induced into an osteogenic
phenotype following re-exposure to osteogenic medium for
10 days (Rediff-DPSCs).
Importantly, results showed that after osteogenic medium
induction, Alizarin Red positive stained calcium nodules
formed in the Rediff-DFPCs were significantly greater
than those observed in Osteo 30 days-DPSCs (Figure 2A).
Spectrophotometric quantification of alizarin red staining
demonstrated higher mineralisation in the Rediff-DPSCs than
Osteo 30 days-DPSCs (Figure 2B). These data demonstrate
that dedifferentiated DPSCs possesses greater potential for
redifferentiation toward the osteogenic phenotype. Importantly,
Dediff-DPSCs retained their immunophenotype similar to that
of undifferentiated DPSCs (Figure 2C).
In addition, we observed that the mRNA expression levels
of osteonectin (ON) and osteopontin (OPN), two markers
of osteogenic differentiation, as well as transcript levels of
two important markers of dental pulp cell differentiation,
including Dmp-1 and Dspp are were considerably increased
during osteogenic differentiation (Osteo-DPSCs). Notably, the
mRNA expression levels of all these genes decreased during the
withdrawal of the osteogenic stimuli (Dediff-DPSCs, Figure 2D).
In addition, as displayed in Figure 2E, Rediff-DPSCs also
showed an increase of ALP activity compared with Osteo 30 days-
DPSCs.
The progression from osteogenic differentiated to
undifferentiated cells is associated with a significant
reduction in the expression of ON, OPN, Dmp-1, and Dspp.
Notably, the mRNA levels of these markers were again
upregulated in Rediff-DFPCs, cultures that were re-exposed to
osteogenic medium.
As Sox2, Klf4, and Nanog are key pluripotent genes necessary
for reprogramming iPSCs and ESC pluripotency (Pennock et al.,
2015), we investigated their expression using a qRT-PCR assay.
Interestingly, results showed a significantly higher expression
of Sox2, Klf4, and Nanog in Dediff-DPSCs with respect to
untreated DPSCs, demonstrating a more primitive phenotype of
dedifferentiated DPSCs (Dediff-DPSCs, Figure 2F). The mRNA
expression levels of these pluripotent genes were decreased
during osteogenic differentiation (Osteo-DPSCs), whereas they
were increased during the withdrawal of the osteogenic stimuli
(Dediff-DPSCs). These results indicated that these stemness
genes play a crucial role in maintaining the self-renewal state in
Dediff-DPSCs. As observed previously for DFPCs, Dediff-DPSCs
also exhibited advantages in proliferation and clonogenicity over
untreated DPSCs (Supplementary Figure 5).
DISCUSSION
In our study, we analysed the osteogenic differentiation potential
of redifferentiated DSCs (DFPCs and DPSCs) compared to
osteogenic differentiated DSCs. Results showed that following
osteogenic differentiation and dedifferentiation in vitro, both
DSC types exhibited enhanced osteogenic differentiation
potential. We also observed that the transcription factors Sox2,
Klf4, and Nanog, key pluripotent genes, were upregulated after
the dedifferentiation process of DSCs. Both dedifferentiated
DSCs were characterised by an elevated mRNA expression level
of Sox2, Klf4, and Nanog. It is well known that these transcription
factors are essential for the maintenance of pluripotency, and
therefore, we hypothesise that they could play a crucial role
in the dedifferentiation process in these cells. Although it is
well known that pluripotent genes such as Sox2 and Nanog are
critical for the maintenance of the pluripotency of embryonic
stem (ES) cells and induced pluripotent stem cells (iPSC), it has
been shown that these genes play a similar role also in adult
stem cells (Rui et al., 2015). For example, the overexpression
of Nanog and Oct4 or Sox2 can improve the stemness and
osteogenesis of human bone marrow MSCs (Go et al., 2008; Liu
et al., 2009). Therefore, pluripotent genes are not only essential
for self-renewal and pluripotency of ES cells and iPSCs, but also
for MSCs such as DSCs.
Similar results were previously reported by Rui et al.
(2015) who studied dedifferentiated bone marrow stem
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FIGURE 2 | Osteogenic differentiation (Osteo-DPSCs), dedifferentiation (Dediff-DPSCs) redifferentiation (Rediff-DPSCs) of DPSCs and osteogenic differentiation for
30 days (Osteo 30 days-DPSCs) used as control. (A) Alizarin red stain images showing calcium deposition in DPSCs, Osteo-DPSCs, Dediff-DPSCs, Rediff-DPSCs,
and Osteo 30 days-DPSCs. (B) Alizarin red quantification showing mineralised deposits in Osteo-DPSCs, Dediff-DPSCs, Rediff-DPSCs, and Osteo 30 days-DPSCs.
(C) Cell surface markers of DPSCs and Dediff-DPSCs. (D) Relative expression levels of ON, DMP-1, DSPP, and OPN assayed by qRT-PCR in DPSCs,
Osteo-DPSCs, Dediff-DPSCs, Rediff-DPSCs, and Osteo 30 days-DPSCs. mRNA HPRT levels were used as control. Results are shown as mean ± SD (n = 3),
*P < 0.05; **P < 0.01. (E) Relative ALP activity in Osteo-DPSCs, Dediff-DPSCs, and Rediff-DPSCs compared to DPSCs control. (F) mRNA expression of the
stemness-associated genes Sox2, Klf4, and Nanog in Osteo-DPSCs, Dediff-DPSCs, Rediff-DPSCs, and Osteo 30 days-DPSCs with respect to DPSCs. *P < 0.05.
cells (BMSCs). In their work, they demonstrated that the
mRNA expression levels of Sox2 and Nanog were increased
in dedifferentiated BMSCs compared with untreated
cells. Our results, together with those described above,
suggest that the improvement of MSC potency observed
during the dedifferentiation process could be related to the
increased expression of Sox2 and Nanog. Indeed, the induced
alteration of gene expression observed in dedifferentiated
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DSCs could confer an extended differentiation potential to
these cells.
Importantly, here we also demonstrated for the first time
that the modulation of culture conditions by altering the
levels of osteogenic inducing factors could be used in human
DSCs to induce the dedifferentiation process. Interestingly,
this dedifferentiation strategy can increase the osteogenic
differentiation capacity of DSCs compared with the standard
method to differentiate DFPCs or DPSCs into osteogenic-like
cells in vitro. Importantly, Rui et al. obtained similar results to
ours and demonstrated that this differentiation strategy could be
used to enhance the osteogenic therapeutic potential of BMSCs
(Pennock et al., 2015; Rui et al., 2015).
Interestingly, it has been shown that epigenetic changes
can regulate stem cell differentiation and dedifferentiation.
Indeed, particular patterns of histone modifications and DNA
methylation have an essential role in stimulating DPSC
differentiation toward the osteogenic lineage (Paino et al.,
2014). Two independent studies have demonstrated that histone
deacetylase (HDAC) inhibition with valproic acid significantly
improved mineralised matrix formation by improving the
expression of bone glycoproteins involved in the formation
of the mineralised matrix (Paino et al., 2014; Duncan et al.,
2016). However, HDAC inhibitors could not easily be utilised
in vivo to enhance the osteogenic differentiation potential
of DPSCs. Thus, the development of an alternative strategy,
such as the dedifferentiation process described here, which
is able to reinforce the osteogenic differentiation potential of
cells is needed.
While in vitro evidence indicates that dedifferentiated SCs
provide a promising cell source for clinical applications, no
clinical studies have yet been performed using this approach.
Here, we have identified an alternative method to enhance the
osteogenic potential of DSCs that could provide hypothetical
clinical benefits with respect to the use of undifferentiated cells.
Naïve DSCs, like other MSC types, exhibit relatively low
cell survival rates and differentiation potential in vivo. This
finding can significantly reduce the effectiveness of stem cell
therapies, and thus their clinical usage. To avoid this problem,
we propose the use of cells having a higher osteogenic potential
that can be relatively easily derived by using a physiological
approach. The dedifferentiation process can be considered a
physiological mechanism since it exists in various tissues and
organs from animals, amphibians and plants (Yao and Wang,
2020). For example, cardiomyocytes and Schwann cells can
dedifferentiate during cardiac regeneration and nerve injury,
respectively (Yao and Wang, 2020). Thus, dedifferentiation is
mechanistically associated with natural regeneration since it is
part of the physiological response to injury in numerous organs
(Merrell and Stanger, 2016).
Thus, due to their enhanced ability to differentiate toward
the osteogenic commitment phenotype, instead of using naïve
DSCs, we propose the use of dedifferentiated DSCs for bone
therapeutic purposes.
The data generated in this study has the potential to be
translated for the development of novel and more efficacious
therapeutic approaches for human bone and dental tissue
regeneration. Despite the scientific literature reporting several
TABLE 1 | Primer details used for qRT-PCR analysis.
Gene symbol Sequence (5′–3′) NCBI accession
number
Runx-2a Forward: ATGTGTGTTTGTTTCAGCAGCA NM_001278478.2
Reverse: TCCCTAAAGTCACTCGGTATGTGTA
Klf4b Forward: CCATCTTTCTCCACGTTCG NM_004235.4
Reverse: AGTCGCTTCATGTGGGAG
Sox2c Forward: GACTTCACATGTCCCAGCACTA NM_003106.3
Reverse: CTCTTTTGCACCCCTCCCATT
Nanogd Forward: ATTCAGGACAGCCCTGATTCTTC NM_024865.3
Reverse: TTTTTGCGACACTCTTCTCTGC
HPRTe Forward: TGACACTGGCAAAACAATGCA NM_000194.2
Reverse: GGTCCTTTTCACCAGCAAGCT
ONf Forward: TGCATGTGTCTTAGTCTTAGTCACC NM_001309443.2
Reverse: GCTAACTTAGTGCTTACAGGAACCA
OSCg Forward: TGAGAGCCCTCACACTCCTC NM_199173.6
Reverse: ACCTTTGCTGGACTCTGCAC
DMP-1h Forward: GTGAGTGAGTCCAGGGGAGATAA NM_004407.3
Reverse: TTTTGAGTGGGAGAGTGTGTGC
DSPPi Forward: CTGTTGGGAAGAGCCAAGATAAG NM_014208.3
Reverse: CCAAGATCATTCCATGTTGTCCT
OPNj Forward: CAGTTGTCCCCACAGTAGACAC NM_001040058.1
Reverse: GTGATGTCCTCGTCTGTAGCATC
aRunx-2, RUNX family transcription factor; bKlf4, kruppel-like factor 4; cSox2, SRY-related HMG-box 2; dNanog, homeobox transcription factor Nanog; eHPRT,
hypoxanthine phosphoribosyltransferase; f ON, osteonectin; gOSC, osteocalcin; hDMP-1, dentin matrix acid phosphoprotein-1; iDSPP, dentin sialophosphoprotein; jOPN,
osteopontin.
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tissue engineering strategies involving MSCs (Paduano et al.,
2016, 2017; Posa et al., 2016; Ballini et al., 2017, 2018; Marrelli
et al., 2018) or biomimetic materials (Marrelli et al., 2013; Barry
et al., 2016; Tatullo et al., 2018), biomedical researchers continue
to face key difficulties which hinder translational approaches
for bone regeneration, including issues relating to patient safety
following extended cell manipulation (Marrelli et al., 2013;
Cantore et al., 2016; Duncan et al., 2016; Marrazzo et al., 2016;
Spagnuolo et al., 2020). Importantly, the approach described here
requires a relatively simple and safe methodology that does not
modify the biological characteristics of the cells.
A limitation of this study is the current lack of evaluation
of the multi-differentiation potential of dedifferentiated DSCs.
Currently, we have only focused on the evaluation of the
osteogenic differentiation potential of dedifferentiated DSCs.
We believe that the knowledge of DSC physiology in terms
of dedifferentiation and redifferentiation could enhance the
development of novel and more competent therapeutic strategies
for human bone regeneration. The significance of this study is
its exploration of the possibility to use dedifferentiated DSCs
as an alternative stem cell source for bone tissue engineering.
Importantly, our strategy requires the use of good manufacturing
procedures that do not alter the biological features of these
accessible cells and thus, it would also be ethically acceptable.
It is essential to underline that both types of DSCs studied
were isolated using an enzymatic digestion strategy. Therefore,
although we observed that the population of dedifferentiated
DSCs possesses a phenotype distinct from their undifferentiated
counterpart, we are aware that there is phenotypic heterogeneity
in each DSC population. Consequently, the heterogeneity of
the DSC population could make the generalisation of findings
difficult, and therefore, future studies are necessary to generate
a standardised protocol.
CONCLUSION
Our results show for the first time that under physiological
conditions, it is possible to induce the dedifferentiation of
DSCs. Importantly, dedifferentiated DSCs exhibit an enhanced
potential for osteogenic differentiation compared with their
undifferentiated counterpart. Therefore, the dedifferentiation
strategy could be potentially used to enhance the osteogenic
therapeutic potential of DSCs. Furthermore, in vivo studies are
necessary to evaluate the therapeutic efficacy of dedifferentiated
DSCs in vivo and shed light on the molecular mechanisms
involved in DSC dedifferentiation. In conclusion, we provide a
novel approach in dental stem cell biology, in which the rerouting
of DSCs fate could offer new therapeutic opportunities.
MATERIALS AND METHODS
Isolation and Application of Dental Stem
Cells
In this study, two types of human dental stem (DSCs)
were studied and included: dental follicle progenitor stem
cells (DFPCs) and dental pulp stem cells (DPSCs). Freshly
isolated DFPCs and DPSCs were regarded as being at the
undifferentiated stage.
DFPCs and DPSCs were isolated as previously described
(Chatzivasileiou et al., 2013; Marrelli et al., 2015; Tatullo et al.,
2015a,b; Paduano et al., 2016, 2017). DSCs were obtained
from healthy volunteers, who provided informed consent at
the Calabrodental Dental Clinic (Crotone, Italy). The study was
performed under guidelines approved by the Ethical Committee
at the Calabrodental Dental Clinic (Ethical agreement number
CBD-001/TRI/2020). Briefly, impacted third molars were rinsed
twice in PBS containing streptomycin (100 µg/mL) and penicillin
(100 U/mL). Dental pulp tissues were separated from the
crown and root, and the freshly extracted dental follicle was
separated from the mineralised tooth. Collected dental pulp tissue
and dental follicles were minced and immersed in a solution
containing dispase (4 mg/mL) and type I collagenase (3 mg/mL)
at 37◦C for 60 min. Each cell suspension was filtered using Falcon
strainers (70 µM) and incubated in basal media comprised of
alpha-MEM culture medium containing 10% FBS (Invitrogen,
Carlsbad, California, United States), streptomycin (100 mg/mL),
glutamine (2 mM) and penicillin (100 U/mL). Both DSCs were




Cells were plated into 100-mm cell culture dishes at a cell density
of 3 × 105 (DFPCs) and 4 × 105 DPSCs until reaching a
confluence of 60–70%. Then, to induce osteogenic differentiation,
undifferentiated (freshly isolated) DFPCs and DPSCs were grown
in osteogenic medium containing α-MEM (Sigma, St. Louis, MO,
United States) supplemented with 50 µg/mL L-ascorbic acid,
5 mM β-Glycerophosphate, 10 nM dexamethasone and 20% FBS
(Invitrogen, Carlsbad, CA, United States), for 10 days (Osteo-
DFPCs and Osteo-DPSCs) according to previously described
procedures (Marrazzo et al., 2016; Paduano et al., 2017).
Subsequently, the osteogenic medium was replenished with basal
media, and subsequently, cells were grown for a further 10 days
(Dediff-DFPCs and Dediff-DPSCs). These cells were considered
in a dedifferentiated stage (Dediff).
The basal medium was then again replaced with osteogenic
medium for 10 days (Rediff-DFPCs and Rediff-DPSCs).
Importantly, DFPCs and DPSCs cultured in osteogenic medium
for 30 days were used as a positive control for osteogenic
differentiation (Osteo 30 days-DPSCs). Mineralisation of DFPCs
and DPSCs were observed on day 10 (Osteo-DFPCs and Osteo-
DPSCs), at day 20 (Dediff-DFPCs and Dediff-DPSCs) and day
30 (Rediff-DFPCs, Rediff-DPSCs, Osteo 30 days-DPSCs. Since
DFPCs exhibit a proliferative rate higher than DPSCs, instead of
at 10 days, they can be induced toward the osteogenic lineage in
the presence of osteogenic medium for 7 days.
Briefly, on the indicated day, cells were rinsed with PBS
and fixed with paraformaldehyde 4% (Sigma, St. Louis, MO,
United States) at room temperature for 20 min. A 5 mg/mL
concentrated solution of Alizarin Red (Sigma, St. Louis, Missouri,
United States) was added to both cell types for 30 min, and the
quantification of Alizarin Red was obtained as we have previously
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described elsewhere [16]. Briefly, cell samples were cultivated
in 10% acetic acid and boiled for 10 min. After centrifugation,
samples were evaluated at a wavelength of 405 nm using a
Multiskan Go Spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, United States) (Paduano et al., 2017).
Gene Expression Analysis
RNA was isolated from DFPCs and DPSCs according to
the Purelink RNA mini kit protocol (Applied Biosystem,
United Kingdom), and the concentrations of extracted RNA were
calculated using a spectrophotometer (Multiskan Go, Thermo
Fisher Scientific, Waltham, Massachusetts, United States). Gene
expression levels were measured by qRT-PCR, as previously
described (Paino et al., 2014; Paduano et al., 2016, 2017;
Tatullo et al., 2017, 2018). Briefly, RNA (200 ng) was reverse-
transcribed according to the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, California,
United States). Subsequently, cDNA samples were amplified
by qRT-PCR using specific primers supplemented with SYBR
Green Master Mix. qRT-PCR reactions were performed using
the following conditions: initial denaturation step at 95◦C for
10 min, followed by 40 cycles of 10 s at 95◦C and 1 min at
60◦C. The specificity of PCR products was checked by melting
curve analysis. After amplification, mRNA expression levels
of the target genes were calculated by the 2-11Ct method.
Hypoxanthine phosphoribosyltransferase (HRPT) was used as
a control to normalise the levels of mRNA in all samples. See
Table 1 for primer details.
Alkaline Phosphatase (ALP) Assay
ALP activity was analysed using the alkaline phosphatase assay
kit (ABCAM). Briefly, for each condition, cells were lysed and
centrifuged. Supernatants were collected for the detection of
ALP activity as described by the manufacturer. Absorbance was
measured at 405 nm, and values were normalised to the total
protein per volume of lysate.
Statistical Analysis
Data are shown as mean ± SD from three independent
experiments in triplicate. Results were analysed by GraphPad
Prism software, and values were indicated statistically significant
when ∗P < 0.05 and ∗∗P < 0.01.
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